Profile: Astrazeneca LP offers a full range of products in five therapeutic areas, which treat conditions & diseases including asthma, gastroesophageal reflux disease & heart disease. Our Nexium® is a proton pump inhibitor, which is approved for heartburn & other symptoms associated with gastroesophageal reflux disease (GERD) and for the healing of erosive esophagitis. Our Accolate (zafirlukast) is indicated for the prophylaxis and chronic treatment of asthma in adults & children. Our Lexxel(enalapril maleate felodipine ER) is a combination products, consisting of an outer layer of enalapril malleate surrounding a core tablet of an extended release felodipine formulation. It is indicated for the treatment of hypertension.
The company has revenues of < USD 1 Million, has ~6000 employees.
FDA Registration Number: 3006316363